Luteolin is known to have anticancer activity in various ca
ncers. Recent studies have shown that luteolin glyco-
sides, such as luteolin-8-
C
-
β
-fucopyranoside, 7-methoxy-luteolin-8-C-
β
-(6- deoxyxylopyranos-3-uloside) and lu-
teolin-8-C-
β
-
D
-glucopyranoside, flavonoid
s that are present in
Arthraxon hispidus
, exert antimigratory and anti-
invasive effects, but no cytotoxic effect in estrogen
receptor-positive MCF7 breast cancer cells. In the present
study, we further investigated and compared differential effects of luteolin and its glycosides in MDA-MB-231
triple-negative breast cancer cells. Lute
olin suppressed the expression of matrix metalloproteinase-9 and inhibited
migration and invasion in MDA-MB-231 cells treated with the tumor promotor 12-O-tetradecanoylphorbol-13-
acetate at non-cytotoxic concentrations (0, 5, and 10
μ
M). Furthermore, at cytotoxic concentrations (20 and 40
μ
M), luteolin induced apoptosis via extrinsic and intrinsic pathways in MDA-MB-231 cells. However, luteolin
glycosides did not exert any cytotoxic, antimigratory, or anti-invasive effect in MDA-MB-231 cells
.
In brief,
l
u-
teolin had both antimetastatic and cytotoxic effects on
MDA-MB-231 cells, whereas luteolin glycosides had no
effect on this cell line. Taking together
the present results and our previous findings on the differential effects of
luteolin and its glycosides on MDA-MB-231 and MCF-7 br
east cancer cells, luteolin and its glycosides can be
suggested as a potential candida
te for breast cancer therapy
